TABLE 1:
Cohort Description and Clinical Characteristics
| Patient No. | MS Type | Age (y) | Sex | EDSS Score | MS Duration (y) | DMT at Time of First MRI | DMT at Time of Second MRI | Interval Between First MRI and Second MRI (mo) | No. of Lesions > 3 mm | No. of Paramagnetic Rim Lesionsa |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RR | 49 | M | 1.5 | < 1 | None | None | 2 | 10 | 2 |
| 2 | RR | 33 | F | 1.5 | 7 | RTX | RTX | 5 | 20 | 0 |
| 3 | PP | 28 | F | 6 | 1 | None | OCZ | 2 | 6 | 3 |
| 4 | SP | 64 | M | 4 | 30 | GA | TER | 14 | 23 | 2 |
| 5 | RR | 37 | M | 1.5 | < 1 | GA | GA | 6 | 3 | 0 |
| 6 | SP | 56 | M | 6.5 | 15 | None | None | 18 | 28 | 1 |
| 7 | RR | 41 | F | 1.5 | 6 | OCZ | OCZ | 3 | 7 | 0 |
| 8 | RR | 49 | F | 3 | 11 | GA | TER | 5 | 19 | 0 |
| 9 | SP | 64 | F | 6.5 | 45 | ALZ | ALZ | 11 | 24 | 1 |
Note—MS = multiple sclerosis, EDSS = expanded disability status scale (a method of quantifying disability in MS and monitoring changes in the level of disability over time), DMT = disease-modifying therapy, RR = relapsing remitting, RTX = rituximab, PP = primary progressive, OCZ = ocrelizumab, SP = secondary progressive, GA = glatiramer acetate, TER = teriflunomide, ALZ = alemtuzumab.
a
Values are from 3-T MRI consensus reading.